Molecular pathology services company Acupath Laboratories Inc reported on Friday the availability of COVID-19 testing via the US FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo kit in New York City area and beyond, to help the region reopen.
The company added that the test is highly sensitive and the results are available within 24 to 48 hours.
According to the company, it is one of the few labs targeting regions of three coronavirus genes: orf-1ab, S protein, N protein, as well as MS2 phage control.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT